HBPCF Stock UPDATES Helix Biopharma Corp. (HBPCF) 1.5061 08/30/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Helix Biopharma Corp. (HBPCF) 1.5061 $HBPCF

Helix BioPharma Corp. Appoints New Independent Chair of the Board
Marketwire Canada - Mon Jul 21, 8:15AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Mr. Yvon Bastien as the new Chair of the board effective July 17, 2014. Mr. Bastien has served as an independent director of the Company since December 2013 and remains the Chair of the board's Governance & Compensation Committee. Mr. Robert Verhagen has served as Interim Chair since December 2013 and remains a Director of the Company and President and CEO.

Helix BioPharma Corp. Initiates Enrollment for Ninth Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47
Marketwire - Tue Jul 15, 7:32AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the ninth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland ("LDOS002" . This follows completion of the first treatment cycle in the three patients enrolled in the eighth dose level cohort, in which L-DOS47 therapy was well tolerated, as reviewed by the Trial Steering Committee.

Helix BioPharma Corp. Announces Completion of Private Placement
Marketwire - Fri Jul 11, 7:00AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has completed a private placement with net proceeds in excess of CAD5.4 million, after fees and expenses associated with the placement.

Helix BioPharma Corp. Announces the Receipt of Subscription Agreements for a Net CAD5.4 Million Private Placement
Marketwire Canada - Mon Jul 07, 6:25AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has received private placement subscription agreements for common shares and warrants for aggregate net proceeds in excess of CAD5.4 million after expected expenses. Proceeds of the placement will be used for working capital to support the Company's expanding clinical trial initiatives.

Global Human Papillomavirus Infections Pipeline Analysis 2014
M2 - Thu Jun 19, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r42gfc/human) has announced the addition of the "Human Papillomavirus Infections Pipeline Analysis" report to their offering. Currently there is significant amount of research being undertaken to study the process of HPV infection causing precancerous changes in normal cells. Also, methods to prevent and manage this situation are also being analyzed. A majority of these studies were previously focusing on cervical cells in women. But in recent years, the realm of research has been extended to other tissues also in which HPV may cause cancer, such as the oropharynx and anus. Also, many organizations are analyzing the use of second-generation preventive vaccines along with therapeutic HPV vaccines, which could possibly prevent the development of cancer among women previously infected with HPV. Such an ideal vaccine strategy would combine a preventive and therapeutic vaccine, which would help in a major way. The mechanism of the HPV vaccines is similar to the other immunizations which help in protecting against viral infections. It has been observed and analyzed that the unique surface components of HPV have the capability to create an antibody response which could possibly protect the human body against infection. These components could thus be used as a basis of the vaccine. There are only 2 HPV vaccines which are currently marketed across the globe. Both these vaccines are prepared using the recombinant technology, which is taken from purified L1 structural proteins which self assemble to form HPV type-specific empty shells or virus-like particles (VLPs). Since there are no therapeutic HPV vaccines available at present which have proved their efficiency in the clinical trials, there is still a lot of work which is required in this field, thus opening a large window of opportunities. There have been some technological advancements in the past 4-5 years. The future is also likely to continue to witness similar technological and medical success in terms of new drugs and efficient vaccines, with the help of adequate funding. Certain developments like a new treatment to reduce transmissibility in drug users and new efforts to strengthen the immune system have the potential to develop further and provide better healthcare services to the patients in the future. Thus, there needs to be more focus being given to increasing the knowledge and awareness about HPV infections and the ways and methods to treat it, either through drugs or through vaccines. Human Papillomavirus Infections Vaccine Pipeline Analysis - Report Highlights: - Human Papillomavirus Vaccine Market Overview - Marketed Drug Profiles & Patent Analysis - Clinical Trial Insight by Phase & Country - Drug Clinical Development Phase: 47 - Suspended & Discontinued Drug Profiles: 46 - Competitive Landscape Companies Mentioned - Advanced Viral Research - BioSphings, - Biogen Idec, - EyeGene, - Helix BioPharma, - Inviragen, - MedImmune, - Merck & Co, - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/r42gfc/human

Helix BioPharma Corp. Announces Fiscal Q3 2014 Results
Marketwire - Thu Jun 12, 8:02AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced financial results for the three and nine-month periods ended April 30, 2014 and 2013.

Helix BioPharma Corp. Announces Appointment of New Director and Observer to the Board of Directors
Marketwire Canada - Tue Mar 11, 4:00PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced the appointment of Mr. Sylwester Cacek to the board of directors. Mr. Cacek's appointment was effective March 7, 2014.

Helix BioPharma Corp. Initiates Enrollment for Seventh Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47
Marketwire Canada - Tue Feb 18, 4:42PM CST
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the seventh dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland. This follows completion of the first treatment cycle of the three patients enrolled in the sixth dose level cohort, in which L-DOS47 therapy was well tolerated as reviewed by the Trial Steering Committee.

Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2013 Report
M2 - Mon Jan 27, 2:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/76wqwr/genital_warts) has announced the addition of the "Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2013" report to their offering. 'Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata). Scope - A snapshot of the global therapeutic scenario for Genital Warts (Condylomata Acuminata). - A review of the Genital Warts (Condylomata Acuminata) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Genital Warts (Condylomata Acuminata) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Genital Warts (Condylomata Acuminata) Overview Therapeutics Development Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview Pipeline Products for Genital Warts (Condylomata Acuminata) - Comparative Analysis Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies Genital Warts (Condylomata Acuminata) - Pipeline Products Glance Clinical Stage Products Early Stage Products Genital Warts (Condylomata Acuminata) - Products under Development by Companies Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development Genital Warts (Condylomata Acuminata) - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Companies Mentioned Helix BioPharma Corp. Inovio Pharmaceuticals, Inc. NanoViricides, Inc. G&E Herbal Biotechnology Co., Ltd. Anaconda Pharma Foamix Ltd. Telormedix SA Genetic Immunity, Inc Xiamen Amoytop Biotech Co., Ltd. For more information visit http://www.researchandmarkets.com/research/76...ital_warts About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Director of Helix BioPharma Corp. Acquires a Further 1,000,000 Common Shares
Marketwire Canada - Fri Jan 10, 9:37AM CST
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company dedicated to developing drugs for prevention and treatment of cancer, today announced that it has been advised by Dr. Marek Orlowski, a member of the board of directors of Helix and Chairman of the Supervisory Board of Helix Polska, that he has purchased 1,000,000 previously issued and outstanding shares of Helix for a total purchase price of approximately CAD$1.72 million since December 30, 2013.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innogen's Arcera Deal Tests Its GLP-1 Global Reach

Updated Category News Views 32

A License Deal With Actual Cash Attached Drug licensing announcements can smell like expensive perfume: plenty of promise, hard to tell what is really in the bottle. This one at least arrives with a concrete number. Innogen Pharmaceuticals will receive US$38 million in upfront and near-term milestone payments from Arcera Life Sciences for Efsubaglutide Alfa, including a...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 24

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 56

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Shenzhen's Vertical Factories Put Robotics on Fast Track

Updated Category News Views 44

A truck climbing to a ninth-floor factory is the sort of detail that cuts through the usual innovation fog. Shenzhen's Honghualing industrial base in Nanshan is built around that odd-looking reality: keep engineers, component makers, automated lines and test customers stacked close together, then squeeze time out of the process. For anybody watching robotics, LiDAR and...

Continue Reading
Wallstreet Sand Hands Its Massive Permian Plant to Wilbanks

Updated Category News Views 210

A sand plant can brag about acreage and horsepower all day, but frac crews remember who kept material arriving when a completion schedule got ugly. That is the real backdrop to PI Holdings and Wallstreet Sand Co. naming Blaine Wilbanks president of both businesses on November 18, 2026. This is not a ceremonial chair swap. Wallstreet has built an enormous Permian sand...

Continue Reading
LLCP Backs Empower in UK Infrastructure Services Push

Updated Category News Views 136

A majority cheque has landed in a business built around unglamorous work that cannot be wished away: keeping mechanical and electrical systems installed, refurbished and maintained. On November 18, LLCP said it completed a majority investment in London-headquartered Empower Technical Services alongside chief executive Nicholas Manning, co-founders Florian Kronawitter and...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 106

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 82

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 20

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
GomSpace's €8M Lunar Deal Pushes Mission Ambitions

Updated Category News Views 41

Moon hardware is where small-space dreams either grow teeth or chew through cash, and GomSpace has just taken another meaningful bite. The company has secured an €8 million, or 89.1 million Swedish kronor, contract for the second phase of a lunar mission program with an unnamed leading North American space company. For GOMX, this is not some vague laboratory...

Continue Reading

Top 5 Most Recently Viewed Articles

TCL NXTPAPER 70 Pro: Pioneering Eye-Care Technology Innovation

Updated Category News Views 159

TCL NXTPAPER 70 Pro Takes Center Stage at Award Ceremony TCL, a renowned name in the display technology sector, has recently celebrated a significant achievement. The TCL NXTPAPER 70 Pro smartphone has been awarded the esteemed Eye-Care Display Technology Gold Award during a prestigious ceremony. This momentous occasion unfolded at the renowned Global Top Brands Awards...

Continue Reading
Sky Quarry Advances Its Waste Asphalt Shingle Facility Plans

Updated Category News Views 97

Sky Quarry Advances Its Waste Asphalt Shingle Facility Plans Sky Quarry Inc. (NASDAQ: SKYQ) is making significant strides toward enhancing the waste-to-energy industry with its innovative Waste Asphalt Shingle Modular Facility. Situated in Woods Cross, Utah, this facility is currently at an impressive stage of completion, standing at 80%. This marks a pivotal moment for...

Continue Reading
Bell Canada’s Strategic Move to Redeem Debentures Early

Updated Category News Views 322

Bell Canada Announces Early Redemption of Debentures Bell Canada recently made an important announcement regarding its financial strategies that speak volumes about its commitment to prudent management. The company revealed plans to redeem its outstanding Cdn $750 million principal amount of 3.55% Debentures, Series M-41, before their maturity date. This redemption is set...

Continue Reading
Exciting Housing Announcement: Key Insights for Communities

Updated Category News Views 174

Anticipating New Housing Developments Media outlets are set to cover an important housing announcement with significant implications for local communities. This event highlights the collaboration between government officials and community leaders focused on addressing housing needs and enhancing infrastructure in various regions. Key Officials Present at the Event The...

Continue Reading
Innovative Partnership Aims at Transforming Material Research

Updated Category News Views 284

Exciting Collaboration to Enhance Material Research In a groundbreaking partnership, CAS, a division of the American Chemical Society, has joined forces with PetroChina Shanghai Advanced Materials Research Institute Co., Ltd. This collaboration aims to utilize the CAS SciFinder Discovery Platform™ to expedite the research and development of advanced chemical materials....

Continue Reading